Long term cognitive outcomes of prematurely born infants: A longitudinal follow‐up of Denver II, Bayley III and WISC‐IV Tests

2021 ◽  
Author(s):  
Meltem Çobanoğulları Direk ◽  
Khatuna Makharoblidze ◽  
Eyşan Sevimli ◽  
Yalçın Çelik ◽  
Bahar Taşdelen ◽  
...  
2012 ◽  
Vol 30 (15_suppl) ◽  
pp. 2006-2006 ◽  
Author(s):  
Richard Charles Curry ◽  
Denise Correa ◽  
Jeffrey J. Raizer ◽  
Sean Aaron Grimm ◽  
Rose Lai ◽  
...  

2006 Background: After promising early results in the pilot phase (N= 30) reported by Shah 2007, we report on final results of a multicenter phase II study (N=52) in newly diagnosed PCNSL combining R-MPV-A and rdWBRT, expanded to address long-term disease control and cognitive outcomes in pts who actually received rdWBRT. Methods: Pts received 5 cycles of R-MPV (MTX dose: 3.5g/m2). Those with partial response (PR) received additional 2 cycles. Pts with a complete response (CR) after 5-7 cycles received rdWBRT (23.4 Gy), otherwise standard WBRT was offered (45 Gy). Consolidation cytarabine was given to all pts. Primary end-point was 2-y progression-free survival (PFS) in pts receiving rdWBRT (n=30 pts in CR required). Exploratory end-points included comprehensive neuropsychological testing, white matter changes (WMC) analysis (Fazekas scale) and apparent diffusion coefficient (ADC) on MRI. Results: Accrual was completed (N=52; 22 women); median (med) age= 60 (30-79); med KPS= 70 (50-100). In total, 31 (59%) pts were assessable for the primary endpoint (achieved a CR after induction and received rdWBRT). The 2-y PFS for this group was 78% (95% ci: 64%- 92%); med PFS= 7.7 y; the med OS was not reached (med follow-up= 6y); 3y-OS= 88% (ci 70-95); 5y-OS= 81% (ci 62-91). Cognitive testing showed improvement in executive function (P < 0.01) and verbal memory (P < 0.05) following induction chemotherapy; follow-up scores remained stable across the various domains. Minimal WMC developed in long term survivors: 36% of pts showed no change in Fazekas’ scores, 64% of pts developed scores 1 or 2 and no pt showed scores 3-6. The intent-to-treat (n=52) med PFS was 3.3y; med OS= 6.6 y. Differences in ADC values did not predict response (p=0.15), PFS (p=0.41) or OS (p=0.48). Conclusions: Consolidation rdWBRT is a highly effective and safe treatment for newly diagnosed PCNSL. Long term follow-up showed robust PFS and OS, comparable or superior to full dose WBRT, with excellent cognitive outcomes and no significant WMC over time. An RTOG randomized trial has been initiated comparing R-MPV-A with vs without rdWBRT.


Neurosurgery ◽  
2000 ◽  
pp. 51-61 ◽  
Author(s):  
Leslie D. McAllister ◽  
Nancy D. Doolittle ◽  
Paul E. Guastadisegni ◽  
Dale F. Kraemer ◽  
Cynthia A. Lacy ◽  
...  

1972 ◽  
Vol 80 (3) ◽  
pp. 501-508 ◽  
Author(s):  
L.O. Lubchenco ◽  
M. Delivoria-Papadopoulos ◽  
L.J. Butterfield ◽  
J.H. French ◽  
D. Metcalf ◽  
...  

2021 ◽  
Vol 5 (Supplement_1) ◽  
pp. 700-700
Author(s):  
Tomiko Yoneda ◽  
Jamie Knight ◽  
Amelia Zhang ◽  
Graciela Muniz-Terrera ◽  
Andrea Piccinin

Abstract Existing literature suggests that in comparison to a single blood pressure (BP) measurement, or the mean of multiple recordings, BP variability (BPV) may reflect dysfunction in cardiovascular regulatory mechanisms, leading to compromised cognitive health. No systematic review has yet synthesized observational reports examining the association between cognition and long-term visit-to-visit BPV. In response, a comprehensive literature search was executed in December, 2019, and updated in December, 2020. Methodological approach was pre-registered (https://osf.io/vmnuq/). Of 1385 reports, 27 met eligibility criteria. Most executed secondary analyses using existing longitudinal datasets of older adults (N=21). Intervals between measurement occasions ranged from 30 days to four years, and follow-up ranged from 0.5-25 years. Most studies computed more than one index of BPV (range=1-6), and all included at least three BP recordings (range=3-12). Given extensive between-study variability in analytic approach (e.g., BPV and cognition treated as continuous and/or categorical variables; number of covariates ranged 0-18), our team determined that meta-analyzing the results would be inappropriate. Despite heterogeneity in study characteristics, the majority (85.2%) reported that systolic BPV (sBPV) was negatively associated with cognition; specifically, higher sBPV was associated with cognitive impairment (N=9), cognitive decline (N=6), and/or risk of dementia (N=5). Four studies also revealed higher sBPV in individuals with dementia compared to controls. Three studies reported no association, while one reported a positive significant association between BPV and cognition. Results were similar for diastolic BPV. Despite considerable heterogeneity in study characteristics, greater variability in visit-to-visit BP appears to be consistently associated with adverse cognitive outcomes.


2021 ◽  
pp. 088307382110358
Author(s):  
Nameirakpam Johnson ◽  
Arushi Gahlot Saini ◽  
Prahbhjot Malhi ◽  
Niranjan Khandelwal ◽  
Pratibha Singhi

Objectives: The objective was to compare the long-term clinical, radiological, and cognitive outcomes in children with single-lesion neurocysticercosis who received 7 or 28 days of albendazole therapy. Methodology: This observational study conducted over 1 year included (1) consecutive children with single-lesion neurocysticercosis who received 7 or 28 days of albendazole therapy in the acute state and (2) completed follow-up for at least 5 years. Seizure recurrence, resolution of lesions, cognition (Malin’s Intelligence Scale for Indian Children), behavior, and school performance (National Initiative for Children Healthcare Quality Vanderbilt Assessment Scale) were assessed. Results: Group A (albendazole for 7 days) comprised 55 children, and group B (albendazole for 28 days) included 48 children. The mean age at the time of diagnosis of neurocysticercosis was 6.6 ± 1.8 years; the mean age at the time of assessment for the study was 13.2 ± 1.2 years. Focal-onset seizures were the most common clinical presentation (58.3%). The majority of lesions were ring-shaped (92.3%) or colloidal (58.2%), with perilesional edema (89.3%). In the long-term follow-up, radiological resolution of the lesions was comparable in both groups. Complete resolution was seen in 52.7% receiving 7 days and 54.2% receiving 28 days albendazole. Seizures recurred in 20% receiving 7 days and 20.8% receiving 28 days albendazole. Overall, a low intelligence quotient (IQ < 70) was seen in 55.3% cases, “somewhat problematic” school performance in 12%, and behavioral abnormalities were present in 20% of the cases. The results were comparable between the 2 groups. Conclusion: Seizure control, radiological resolution of lesion, school performance, cognitive and behavioral outcomes in the long term are comparable in children with single-lesion neurocysticercosis who have received albendazole cysticidal therapy for 7 days and 28 days. Recurrence of seizure is seen with both regimens in the long term, necessitating regular follow-up and discussion regarding the risk of recurrence before a withdrawal of anticonvulsant therapy.


Sign in / Sign up

Export Citation Format

Share Document